Back to top
more

EDAP TMS (EDAP)

(Delayed Data from NSDQ)

$1.25 USD

1.25
47,597

-0.02 (-1.57%)

Updated Aug 6, 2025 03:59 PM ET

After-Market: $1.25 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Strong Segmental Performance to Drive Stryker's Q1 Earnings?

by Zacks Equity Research

SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

Zacks Equity Research

DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?

by Zacks Equity Research

DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.

Zacks Equity Research

Will BAX's Q1 Earnings Improve Following Transformation Completion?

by Zacks Equity Research

Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.

Urmimala Biswas headshot

RMTI Stock Rises 138% in Q3: What Should You Do Ahead of Earnings?

by Urmimala Biswas

Rockwell Medical expects its Q3 results to gain from a high rate of customer conversions toward it compared with its primary competitor.

Zacks Equity Research

CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Urmimala Biswas headshot

Rockwell Medical on Expansion Spree: Should You Buy the Stock Now?

by Urmimala Biswas

This year can be regarded as a momentous period for RMTI's business because this is the first time in its history that it has achieved steady revenue growth.

Zacks Equity Research

EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock

by Zacks Equity Research

When combined with EDAP's Focal One platform, Avenda's Unfold AI enables more accurate and patient-specific treatment options.

Urmimala Biswas headshot

Rockwell Medical Stock Surges 108.5% YTD: Should You Snap it Up Now?

by Urmimala Biswas

RMTI continues to outperform its peers, banking on its focus on optimizing business to drive sustainable profitability and meaningful cash flow generation.

Zacks Equity Research

Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar?

by Zacks Equity Research

Veracyte (VCYT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

New Strong Sell Stocks for October 17th

by Zacks Equity Research

BAYYR, EDAP and FWRD have been added to the Zacks Rank #5 (Strong Sell) List on October 17, 2023.

Zacks Equity Research

SentinelOne (S) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Sentinel One's (S) fourth-quarter fiscal 2023 results are likely to reflect the benefits of strategic integrations and expanding clientele.

Zacks Equity Research

Cooper Companies (COO) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.

Zacks Equity Research

What's in Store for Patterson Companies (PDCO) in Q3 Earnings?

by Zacks Equity Research

Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.

Zacks Equity Research

EDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

EDAP TMS S.A. (EDAP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Zacks.com featured highlights include Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares

by Zacks Equity Research

Immunocore Holdings, Old Second Bancorp, EDAP TMS, Barrett Business Services and MainStreet Bancshares are part of the Zacks Screen of the Week article.

Zacks Equity Research

Best Momentum Stocks to Buy for November 21st

by Zacks Equity Research

ACR, EDAP and H made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 21, 2022.

Zacks Equity Research

New Strong Buy Stocks for November 21st

by Zacks Equity Research

AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.

Nalak Das headshot

5 Stocks With Recent Price Strength to Maximize Your Gains

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are IMCR, EDAP, BBSI, OSBC and MNSB.

Zacks Equity Research

Is EDAP TMS (EDAP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how EDAP TMS S.A. (EDAP) and Paragon 28, Inc. (FNA) have performed compared to their sector so far this year.

Zacks Equity Research

Why Earnings Season Could Be Great for EDAP TMS (EDAP)

by Zacks Equity Research

EDAP TMS (EDAP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Here's Why Momentum in EDAP TMS S.A. (EDAP) Should Keep going

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, EDAP TMS S.A. (EDAP) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter results are likely to reflect strong performance in the Technologies & Equipment business.

Zacks Equity Research

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for discovery business and informatics franchise.

Zacks Equity Research

Is Centene (CNC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Centene (CNC) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

Zacks Equity Research

Here's What Could Help EDAP TMS S.A. (EDAP) Maintain Its Recent Price Strength

by Zacks Equity Research

EDAP TMS S.A. (EDAP) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.